The combined treatment has not been able to reduce markedly the amount of reticulin fibers; however, it has to be underlined that bone marrow cellularity markedly increased, with normal morphology of megakaryocytes. Thus, the good response observed in our case suggests that thalidomide plus rHuEPO may be an option for IMF patients even with advanced disease, unresponsive to the drugs used as monotherapy. In particular, it might be a valid choice also in patients with a strongly increased marrow fibrosis and a suboptimal marrow reserve.
Biological and clinical studies are anyway warranted to better clarify the rationale of thalidomide therapy, the choice of agents active in combination and which subset of patients could benefit more by this treatment.
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This work was supported in part by AIL Pesaro ONLUS. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. 2 It is the first molecular targeted therapy against a causative oncoprotein and the first application of principles of eucaryotic transcription to cancer biology.
Although the mechanisms of ATRA treatment have been largely elucidated, the molecular events downstream of the RAR complexes, especially for the biochemical changes in the cytoplasm, are still unclear. Therefore, using the ATRA-sensitive APL cell line NB 4 as an in vitro model, we undertook a study based on a new method, Fourier-transform infrared (FT-IR) spectroscopy, to monitor the biochemical changes in the process of ATRA-induced myeloid differentiation. FT-IR spectra can provide molecular structure information at the level of chemical bonding. The absorption bands are able to determine the composition of the whole biochemical components. It has been widely used for the analysis of nucleic acids, proteins, glycolipids, bacteria, intact tumor cells and tissues. 3 The certain process of cell life, such as cell division cycle and apoptosis, 4 has also been studied with it. NB 4 cells were treated with different doses (1-1000 nmol/L) of ATRA over different time (0-72 h), with special time and dose events chosen for investigation to monitor the whole course of differentiation. The control and treated cells were collected, washed with physiological saline, and deposited on a calcium fluoride window. Once the cells were dried as a thin circular film in a desiccator under a mild vacuum, their IR spectra were recorded by means of a spectrometer-Spectrum GX FT-IR. Data analysis was performed Correspondence with the software of Spectrum for Windows (Perkin-Elmer Inc., MA, USA). ATRA-resistant NB 4 -derived MR 2 subclone cells (NB 4 -MR 2 ) were used to confirm the results from the opposite side. Human myeloblast leukemia HL-60 cells, being arrested at the myeloblastic-promyelocytic stage, were also employed in comparison with NB 4 cells.
The proliferation of NB 4 cells was suppressed upon treatment with ATRA, with the granulocytic differentiation induced in a timeand dose-dependent manner (Figure 1 ). It was demonstrated by the characteristic morphological changes such as condensed chromatin pattern, segmented nuclei and decreased nucleus/cytoplasm ratio. The expression of CD11b, which is one of the myeloid cell surface markers, increased gradually at the same time. Nitro blue tetrazolium (NBT) reduction tests were in high accordance with it. Cell cycle analysis showed that the increase of the G 0 /G 1 -phase cells and decrease of the S-phase cells were concomitant with the depression of cell proliferation. No evident apoptosis was observed during the whole course because of the little sub-G 1 cell population. Similar results were obtained in HL-60 cells in cytomorphology and NBT reduction tests. On the contrary, NB 4 -MR 2 cells were not induced into differentiation at the same condition.
The representative FT-IR spectra of control and ATRA-treated NB 4 cells were displayed in Figure 2 , showing the characteristic bands of basic biochemical components, such as lipids (3200-2700 cm . It is usually associated with the carbonyl C ¼ O stretching mode in nonhydrogen-bonded ester within phospholipids and fatty acids. Its intensity is an indicator for the relative lipid concentration, suggesting an increase of the C ¼ O ester lipids in the membranes with ATRA treatment. Inasmuch as certain phospholipids are essential for signaling transduction, these changes for plasma membrane may be directly related to specific signaling pathways. In addition, the C-H stretching region (3200-2700 cm À1 ) showed differences in the bands of the methyl and methylene groups, which is typical of lipids. The bands associated with symmetrical stretching vibrations of CH 2 (2855 cm
À1
) and CH 3 (2874 cm À1 ) were distinct, while the asymmetrical ones were centered at 2925 and 2957 cm À1 (Figure 2 ). The density ratio between the bands at 2925 and 2957 cm À1 was calculated, with spectral positions at 3800 and 2300 cm À1 as reference baseline. ATRA treatment made the ratio value higher when the exposure time was increased (Figure 3a) , suggesting a decrease in the number of methyl groups vs methylene groups in differentiated cells. 5 The difference spectrum showed the same results, suggesting more branched aliphatic chains and the changes of packing characteristics, relating to the increased degree of membrane fluidity. It may also explain the morphological changes (eg. smaller size) and cytoplasmic extensions seen in ATRA-treated cells. Indeed, a decrease of cellular volume corresponds to a relative increase in surface area. This may enrich the overall cellular content with fatty acids and phospholipids.
The most striking changes were observable in the 1300-900 cm (Figure 2c ). The area ratio (A 1085 /A 1545 ) was employed and showed good correlation with the differentiation index (the correlation coefficient 40.90, Po0.001), which was calculated by NBT reduction and CD11b expression tests. 6 The increase of the content of carbohydrates, especially those contained in glycolipids and glycoproteins, coincided with previous study by Smolenska-Sym et al. 
Correspondence
The contour changes in the region of 1300-900 cm À1 could be related to the conformation and distribution of nucleic acids/ carbohydrates (Figure 4) . Significantly, the multicomponent absorptions around 1055 cm À1 increased on the side of lower frequency and were broader than untreated ones. A marked shoulder band centered at 1023 cm À1 emerged gradually in the late stage of differentiation. In order to enhance the resolution, the second derivative spectra were calculated and the corresponding band at 1023 cm À1 was found increased distinctly (Figure 4c ). Since the 1023 and 1053 cm À1 bands were both due to the vibrational modes of -CH 2 OH groups and the C-O stretching coupled with C-O bending of the C-OH groups in carbohydrates, it is speculated that The contour changes in the region of nucleic acids/ carbohydrates in the spectra of NB 4 cells during the whole differentiation process. The IR spectra in the region of 900-1300 cm À1 of NB 4 cells when treated with different doses of ATRA for 72 h (a), or exposure to 1 mmol/L ATRA for gradually increased time (b, with the ordinate is the same with a). (c) The secondary derivative spectra corresponding to (b) were shown in the region of 950-1100 cm À1 .
Correspondence the glycosylation of proteins or newly synthesized glycoproteins may play important roles in the myeloid differentiation process. The difference spectrum showed an obvious increase for the band centered at 1154 cm À1 (Figure 2c ). This band assumed a special meaning because it changed from 1170 cm À1 consecutively (Figure 4 ). They are due to the hydrogen-bonded and nonhydrogen-bonded C-O stretching mode of the C-OH groups of serine, threonine and tyrosine in proteins, respectively as well as the C-O groups in carbohydrates, 8 indicating the protein glycosylation and phosphorylation processes more readily take place in the differentiation process. In contrast with the 968 cm À1 band, the band at 1086 cm À1 shifted apparently to lower frequency after ATRA treatment, indicating that the hydrogen bonding interactions within nucleic acids were not as strong as the consistent untreated ones. This, in turn accounted for structural alterations in the chromosomes of differentiated cells, as manifested by morphological observation (Figure 1a In summary, it is possible to use FT-IR spectroscopy to monitor the biochemical events underlying the different phases of ATRAinduced NB 4 cell differentiation. The clearcut spectral changes in lipids, nucleic acids and carbohydrates could lead to several testable hypotheses, providing important insights into the mechanisms of leukemogenesis and normal granulocytic differentiation. One or more spectroscopic parameters may have potential uses as diagnostic indicators to assist treatment decisions for APL patients. FT-IR spectroscopy also has the advantages of good reproducibility, rapid determination, and the possibility of examining untreated microsamples. It may have potential application in clinical study for fast and reagent-free diagnosis. However, such a possibility still requires further exploration.
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis 
TO THE EDITOR
Although chemotherapy induces morphologic complete remission (CR) in most acute myeloid leukemia (AML) patients, many will eventually relapse due to the persistence and subsequent outgrowth of minimal residual disease (MRD). It has been reported that high MRD levels at follow-up and high P-glycoprotein (Pgp, ABCB1) activity at diagnosis correlate with shorter survival. [1] [2] [3] This is less clear for other ABC-transporters such as multidrug resistance protein (MRP1, ABCC1) and breast cancer resistance protein (BCRP, ABCG2). 3 Based on our previous findings of homogeneous distribution of drug efflux capacity over the total blast population at diagnosis and the constancy of both Pgp, MRP1 and BCRP function during the course of disease, including MRD and relapse, 4 we hypothesized that the emergence of MRD and its frequency at follow-up might be a direct resultant of the presence and level of activity of ABC-transporters at diagnosis. No study has been designed thus far to address this question directly, although preliminary evidence favoring this idea has been provided for Pgp:
1,2 patients with high MRD levels after chemotherapy had higher Pgp expression/activity at diagnosis. No such studies have been performed for MRP1 and BCRP. Since we previously found that the majority of AML patients display Pgp and MRP1 activity at diagnosis, whereas BCRP activity was present in 3/26 patients only, 4 we focused this study primarily on the ABC transporters Pgp and MRP1.
For these purposes, we collected after informed consent, bone marrow (BM) samples from AML patients at the time of diagnosis at the VU University Medical Center. A total of 100 patients were included with a median age of 56 years, ranging from 16 to 88, with the following French-American-British classification: M0 (9), M1 (9), M2 (17), M3 (4), M4 (17), M5 (26), M6 (4), MDS (9), not specified (5 
